Jeil Pharma Holdings Inc (002620.KS)
KRW 7990.0
(-3.5%)
KRW 7990.0
(-3.5%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 135.99 Billion KRW | 33.58% |
| 2022 | 101.8 Billion KRW | 17.71% |
| 2021 | 86.49 Billion KRW | -33.27% |
| 2020 | 129.61 Billion KRW | 27.87% |
| 2019 | 101.35 Billion KRW | 37.01% |
| 2018 | 73.97 Billion KRW | 1016.13% |
| 2017 | -8.07 Billion KRW | -129.98% |
| 2016 | 26.93 Billion KRW | 109.52% |
| 2015 | 12.85 Billion KRW | 70.04% |
| 2014 | 7.56 Billion KRW | 19.43% |
| 2013 | 6.33 Billion KRW | -50.01% |
| 2012 | 12.66 Billion KRW | 176.01% |
| 2011 | -16.66 Billion KRW | 15.18% |
| 2010 | -19.64 Billion KRW | 13.19% |
| 2009 | -22.62 Billion KRW | -302.21% |
| 2008 | -5.62 Billion KRW | -51.87% |
| 2007 | -3.7 Billion KRW | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 117.53 Billion KRW | -13.93% |
| 2024 Q1 | 136.55 Billion KRW | 0.42% |
| 2023 Q2 | 118.49 Billion KRW | 4.55% |
| 2023 Q1 | 113.34 Billion KRW | 11.34% |
| 2023 FY | 135.99 Billion KRW | 33.58% |
| 2023 Q4 | 135.99 Billion KRW | -0.01% |
| 2023 Q3 | 136 Billion KRW | 14.77% |
| 2022 Q2 | 105.01 Billion KRW | 20.46% |
| 2022 Q1 | 87.17 Billion KRW | 0.79% |
| 2022 FY | 101.8 Billion KRW | 17.71% |
| 2022 Q4 | 101.8 Billion KRW | -13.64% |
| 2022 Q3 | 117.88 Billion KRW | 12.26% |
| 2021 Q3 | 82.14 Billion KRW | 0.01% |
| 2021 Q4 | 86.49 Billion KRW | 5.3% |
| 2021 FY | 86.49 Billion KRW | -33.27% |
| 2021 Q1 | 77.9 Billion KRW | -39.89% |
| 2021 Q2 | 82.13 Billion KRW | 5.43% |
| 2020 Q4 | 129.61 Billion KRW | -3.38% |
| 2020 Q2 | 121.46 Billion KRW | 22.74% |
| 2020 Q3 | 134.14 Billion KRW | 10.45% |
| 2020 FY | 129.61 Billion KRW | 27.87% |
| 2020 Q1 | 98.95 Billion KRW | -2.37% |
| 2019 Q2 | 51.88 Billion KRW | -13.67% |
| 2019 Q4 | 101.35 Billion KRW | 72.7% |
| 2019 Q1 | 60.1 Billion KRW | -18.75% |
| 2019 Q3 | 58.68 Billion KRW | 13.11% |
| 2019 FY | 101.35 Billion KRW | 37.01% |
| 2018 Q2 | 34.48 Billion KRW | 425.14% |
| 2018 Q3 | 35.07 Billion KRW | 1.7% |
| 2018 FY | 73.97 Billion KRW | 1016.13% |
| 2018 Q1 | -10.6 Billion KRW | -31.36% |
| 2018 Q4 | 73.97 Billion KRW | 110.91% |
| 2017 Q1 | 14.44 Billion KRW | -46.36% |
| 2017 Q2 | -12.18 Billion KRW | -184.3% |
| 2017 FY | -8.07 Billion KRW | -129.98% |
| 2017 Q3 | -11.13 Billion KRW | 8.62% |
| 2017 Q4 | -8.07 Billion KRW | 27.45% |
| 2016 FY | 26.93 Billion KRW | 109.52% |
| 2016 Q4 | 26.93 Billion KRW | 0.0% |
| 2015 Q2 | 877.09 Million KRW | 114.27% |
| 2015 FY | 12.85 Billion KRW | 70.04% |
| 2015 Q3 | 16.42 Billion KRW | 1773.2% |
| 2015 Q1 | -6.14 Billion KRW | -181.3% |
| 2014 Q1 | 10.57 Billion KRW | 67.01% |
| 2014 Q2 | 322.97 Million KRW | -96.95% |
| 2014 Q3 | -4.51 Billion KRW | -1499.18% |
| 2014 Q4 | 7.56 Billion KRW | 267.31% |
| 2014 FY | 7.56 Billion KRW | 19.43% |
| 2013 Q3 | 4.51 Billion KRW | -8.68% |
| 2013 Q4 | 6.33 Billion KRW | 40.26% |
| 2013 Q2 | 4.94 Billion KRW | 67.19% |
| 2013 Q1 | 2.95 Billion KRW | -76.66% |
| 2013 FY | 6.33 Billion KRW | -50.01% |
| 2012 Q3 | 11.6 Billion KRW | 258.03% |
| 2012 Q2 | -7.34 Billion KRW | -42.21% |
| 2012 Q1 | -5.16 Billion KRW | 69.0% |
| 2012 FY | 12.66 Billion KRW | 176.01% |
| 2012 Q4 | 12.66 Billion KRW | 9.08% |
| 2011 FY | -16.66 Billion KRW | 15.18% |
| 2011 Q4 | -16.66 Billion KRW | 41.89% |
| 2011 Q3 | -28.67 Billion KRW | 26.08% |
| 2011 Q2 | -38.78 Billion KRW | -11.9% |
| 2011 Q1 | -34.66 Billion KRW | -76.47% |
| 2010 Q1 | -37.27 Billion KRW | -64.75% |
| 2010 Q2 | -30.85 Billion KRW | 17.23% |
| 2010 FY | -19.64 Billion KRW | 13.19% |
| 2010 Q4 | -19.64 Billion KRW | -15.95% |
| 2010 Q3 | -16.93 Billion KRW | 45.1% |
| 2009 Q3 | -14.68 Billion KRW | -106.76% |
| 2009 Q2 | -7.1 Billion KRW | -73.0% |
| 2009 Q1 | -4.1 Billion KRW | 27.02% |
| 2009 FY | -22.62 Billion KRW | -302.21% |
| 2009 Q4 | -22.62 Billion KRW | -54.08% |
| 2008 Q1 | -3.59 Billion KRW | 3.07% |
| 2008 Q2 | -3.17 Billion KRW | 11.57% |
| 2008 Q4 | -5.62 Billion KRW | -23.1% |
| 2008 Q3 | -4.56 Billion KRW | -43.92% |
| 2008 FY | -5.62 Billion KRW | -51.87% |
| 2007 Q3 | -7.59 Billion KRW | -309.28% |
| 2007 FY | -3.7 Billion KRW | 0.0% |
| 2007 Q2 | 3.62 Billion KRW | 195.63% |
| 2007 Q4 | -3.7 Billion KRW | 51.21% |
| 2007 Q1 | -3.79 Billion KRW | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 8.8 Billion KRW | -1444.964% |
| Dong-A Socio Holdings Co., Ltd. | 572.02 Billion KRW | 76.226% |
| Ildong Holdings Co., Ltd. | 310.87 Billion KRW | 56.255% |
| HANDOK Inc. | 283.45 Billion KRW | 52.024% |
| Kukje Pharma Co., Ltd. | 20.07 Billion KRW | -577.513% |
| Yuhan Corporation | -69.18 Billion KRW | 296.558% |
| Dong-A ST Co., Ltd. | 193.95 Billion KRW | 29.883% |
| SAMSUNG PHARM. Co., LTD. | -3.68 Billion KRW | 3789.595% |
| Hanmi Pharm. Co., Ltd. | 517.88 Billion KRW | 73.741% |
| Hanall Biopharma Co.,Ltd | -32.43 Billion KRW | 519.314% |
| Ilyang Pharmaceutical Co.,Ltd | 75.67 Billion KRW | -79.705% |
| Dong Sung Bio Pharm.Co.,Ltd. | 36.83 Billion KRW | -269.168% |
| MYUNGMOON Pharm co.,Ltd | 82.52 Billion KRW | -64.798% |
| Hana Pharm Co., Ltd. | 25.1 Billion KRW | -441.618% |
| Yuyu Pharma, Inc. | 8.8 Billion KRW | -1444.964% |
| Ilsung Pharmaceuticals Co., Ltd. | -159.84 Billion KRW | 185.076% |
| REYON Pharmaceutical Co., Ltd. | 200.94 Billion KRW | 32.324% |
| Aprogen pharmaceuticals,Inc. | 170.94 Billion KRW | 20.446% |
| JW Holdings Corporation | 480.68 Billion KRW | 71.709% |
| Ildong Pharmaceutical Co., Ltd. | 164.58 Billion KRW | 17.372% |
| Chong Kun Dang Pharmaceutical Corp. | 117.53 Million KRW | -115606.598% |
| JW Pharmaceutical Corporation | 154.37 Billion KRW | 11.906% |
| Shin Poong Pharm.Co.,Ltd. | 2.35 Billion KRW | -5683.633% |
| Hyundai Pharmaceutical Co., Ltd. | 23 Billion KRW | -491.231% |
| Samil Pharmaceutical Co.,Ltd | 174.97 Billion KRW | 22.278% |
| Jeil Pharmaceutical Co.,Ltd | 51.97 Billion KRW | -161.65% |
| Yuyu Pharma, Inc. | 8.8 Billion KRW | -1444.964% |
| Kwang Dong Pharmaceutical Co., Ltd. | 158.29 Billion KRW | 14.091% |
| Daewoong pharmaceutical Co.,Ltd | 358.17 Billion KRW | 62.032% |
| JW Pharmaceutical Corporation | 154.37 Billion KRW | 11.906% |
| Yuhan Corporation | -69.18 Billion KRW | 296.558% |
| Yungjin Pharm. Co., Ltd. | 59.67 Billion KRW | -127.89% |
| Suheung Co., Ltd. | 429.14 Billion KRW | 68.311% |
| JW Pharmaceutical Corporation | 154.37 Billion KRW | 11.906% |
| Samjin Pharmaceuticals Co., Ltd. | 116.23 Billion KRW | -16.996% |
| Korea United Pharm Inc. | 16.42 Billion KRW | -727.95% |
| CKD Bio Corp. | 143.29 Billion KRW | 5.098% |
| Daewon Pharmaceutical Co., Ltd. | 116.06 Billion KRW | -17.166% |
| Dongwha Pharm.Co.,Ltd | -24.06 Billion KRW | 665.179% |
| Whan In Pharm Co.,Ltd. | -44.73 Billion KRW | 404.0% |
| Shin Poong Pharm.Co.,Ltd. | 2.35 Billion KRW | -5683.633% |
| Chong Kun Dang Holdings Corp. | 422.84 Billion KRW | 67.839% |
| Boryung Corporation | 187.72 Billion KRW | 27.559% |
| Bukwang Pharmaceutical Co., Ltd. | -71.84 Billion KRW | 289.298% |
| Ilyang Pharmaceutical Co.,Ltd | 75.67 Billion KRW | -79.705% |
| JW Lifescience Corporation | 26.09 Billion KRW | -421.227% |